Stocks · Healthcare · Biotechnology
10x Genomics, Inc. TXG
$93.50 +5.34% Close, Oct 2, 2026 · NASDAQ · Market cap $11.87B
Strong trend
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Over the past year the stock returned +654.6%, ahead of the S&P 500 by 639.6 percentage points.
- The stock is in an uptrend: above its 200-day average for 243 trading days, with the 50-day average above the 200-day.
- The company holds net cash of $423.7M (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth37Weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 24%
- FCF growth (TTM, YoY)Top 14%
- Revenue growth, 3-year CAGRBottom 43%
- Revenue growth accelerationBottom 22%
Quality73Positive
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 42%
- Gross marginTop 43%
- Operating marginBottom 45%
- Accruals (lower is better)Top 14%
- Net debt / EBITDA (lower is better)Top 4%
- Interest coverBottom 1%
Value59Neutral
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 31%
- Free-cash-flow yieldTop 32%
- EBITDA / enterprise valueTop 37%
- Sales / enterprise valueBottom 22%
Momentum100Exceptional
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 2%
- 6-month returnTop 1%
- 1-year return vs S&P 500Top 1%
- Distance from 52-week highTop 2%
- Trend checklist (0–4)Top 7%
Revisions6Very weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 21%
- Consecutive EPS beatsTop 25%
- Share of analysts rating BuyBottom 13%
- Upside to consensus price targetBottom 2%
Stability43Weak
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 31%
- Maximum drawdown, 3 yearsBottom 20%
- Beta vs S&P 500 (lower is better)Bottom 32%
- Net debt / EBITDA (lower is better)Top 4%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 2.3% | -4.3% | ↓ |
| Gross margin | 69.5% | 70.0% | ↑ |
| Operating margin | -15.6% | -14.3% | ↑ |
| FCF margin | 8.8% | 19.7% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -4.3% | 2.3% | ↓ | Bottom 24% |
| Gross margin | 70.0% | 69.5% | ↑ | Top 43% |
| Operating margin | -14.3% | -15.6% | ↑ | Bottom 45% |
| Net margin | -12.2% | -13.1% | ↑ | — |
| Free-cash-flow margin | 19.7% | 8.8% | ↑ | — |
| Return on invested capital | -9.6% | — | Top 42% | |
| Revenue growth, 3-year CAGR | 7.6% | — | Bottom 43% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -19.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 16.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -53.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -15.13×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -29461.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.05%
- Shareholder yield
- -0.05%
- Share count change, 1 year
- +4.4%
- Share count change, 3-year CAGR
- +3.7%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 7, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 3
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- -18.7%
- Average 2-day reaction, last 8
- -1.4%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $67.30
- Target vs current price
- -28.0%
- Analysts with a rating
- 22
- Share rating Buy or Strong Buy
- 45%
- Consensus rating
- Hold
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +42.4% | -3.9% | +21.7% | +29.9% | — |
| May 7, 2026 | +65.5% | -1.4% | -7.3% | +47.3% | +106.7% |
| Feb 12, 2026 | +31.6% | -8.6% | +0.2% | -1.1% | +12.8% |
| Nov 6, 2025 | -214.3% | -3.6% | +23.7% | +34.5% | +42.9% |
| Aug 7, 2025 | +180.0% | +1.1% | +7.2% | +7.2% | -1.7% |
| May 8, 2025 | +20.0% | +3.9% | +9.7% | +9.6% | +64.6% |
| Feb 12, 2025 | -37.9% | +1.5% | +2.4% | -8.2% | -27.0% |
| Oct 29, 2024 | +11.8% | -0.4% | +5.8% | -3.5% | -6.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.14 | -$0.24 | +42.4% | $151.0M |
| May 7, 2026 | -$0.10 | -$0.29 | +65.5% | $150.8M |
| Feb 12, 2026 | -$0.13 | -$0.19 | +31.6% | $166.0M |
| Nov 6, 2025 | -$0.22 | -$0.07 | -214.3% | $149.0M |
| Aug 7, 2025 | $0.28 | -$0.35 | +180.0% | $172.9M |
| May 8, 2025 | -$0.36 | -$0.45 | +20.0% | $154.9M |
| Feb 12, 2025 | -$0.40 | -$0.29 | -37.9% | $165.0M |
| Oct 29, 2024 | -$0.30 | -$0.34 | +11.8% | $151.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / EBITDA | 408.8× | — | — | Top 37% |
| EV / Sales | 18.55× | — | — | Bottom 22% |
| Free-cash-flow yield | 1.02% | — | — | Top 32% |
| Earnings yield | -0.63% | — | — | Top 31% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 96
- Days above the 200-day average
- 243
- 50-day average slope (20 days)
- +28.7%
- 200-day average slope (20 days)
- +21.1%
- Distance from 50-day average
- +44.3%
- Distance from 200-day average
- +169.1%
- RSI (14)
- 77.0
- Relative volume
- 1.02×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 68.1%
- Volatility vs own 5-year history
- 49th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.45
- Correlation with S&P 500
- 0.32
- Current drawdown from 1-year high
- +0.0%
- Maximum drawdown, 3 years
- -87.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 26, 2021 | Apr 8, 2025 | -96.5% | 993 days | Not yet recovered |
| Feb 12, 2021 | Mar 8, 2021 | -28.3% | 15 days | 20 days (Apr 6, 2021) |
| Oct 16, 2020 | Nov 10, 2020 | -21.2% | 17 days | 41 days (Jan 11, 2021) |
| Jan 22, 2021 | Jan 27, 2021 | -12.7% | 3 days | 11 days (Feb 11, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $11.87B
- EPS, diluted (TTM)
- -$0.59
- Revenue (TTM)
- $616.9M
- 52-week range
- $11.16 – $95.16
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $490.5M | $516.4M | $618.7M | $610.8M | $642.8M |
| Gross profit | $416.4M | $396.0M | $409.3M | $414.5M | $443.9M |
| Operating income | -$52.9M | -$167.9M | -$265.3M | -$194.6M | -$110.9M |
| Net income | -$58.2M | -$166.0M | -$255.1M | -$182.6M | -$43.5M |
| EPS (diluted) | -$0.53 | -$1.46 | -$2.18 | -$1.52 | -$0.35 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $151.7M | $165.0M | $154.9M | $172.9M | $149.0M | $166.0M | $150.8M | $151.0M |
| Net income | -$35.8M | -$49.0M | -$34.4M | $34.5M | -$27.5M | -$16.3M | -$13.5M | -$17.9M |
| EPS (diluted) | -$0.30 | -$0.40 | -$0.28 | $0.28 | -$0.22 | -$0.13 | -$0.10 | -$0.14 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$21.4M | -$33.6M | -$15.2M | $6.7M | $136.1M |
| Capital expenditure | -$101.3M | -$131.7M | -$49.5M | -$12.4M | -$5.9M |
| Free cash flow | -$122.7M | -$165.3M | -$64.7M | -$5.7M | $130.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $40.3M | $21.2M | $19.5M | $10.9M | $6.8M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $552.0M
- Total assets
- $1.03B
- Total liabilities
- $204.5M
- Total debt
- $78.8M
- Net debt
- -$423.7M
- Shareholders’ equity
- $825.5M
As of Jun 30, 2026 (filed Aug 7, 2026).
Short interest
- Shares sold short
- 16,692,300
- Days to cover
- 7.09
- Change vs previous report
- +3.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jul 17, 2006
- 1-for-2